ARCHIVES

“Recalcitrant” Cancers? Committee Rewrite Of Pancreatic Bill Raises New Questions

This article is from The Cancer Letter archive.

Vol. 38 No. 34 | September 14, 2012

Download PDF Visit The Full Archive

Related Articles

AstraZeneca To Pay $335M In Illegal Pricing Penalties.

June 27, 2003

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

Former BMS Executive Bodnar Indicted.

April 25, 2008

Chromosomal Abnormalities Predict Long Median Survival

January 27, 2012

Varmus Pools $13.4 M. To Fund Projects; NCI Gives $2.6 Mil.

December 9, 1994

NCI Should Toughen Deadlines, Quality, in RAID program, Advisory Committee Says.

October 6, 2006